Filtered By:
Specialty: Infectious Diseases

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 742 results found since Jan 2013.

Recent HIV/AIDS News
April 30, 2013: U.S. Preventive Services Task Force Issues Final Recommendation Statement on Screening for HIV “The U.S. Preventive Services Task Force (Task Force) today released its final recommendation statement on screening for HIV. The Task Force recommends that clinicians screen all people aged 15 to 65, as well as younger adolescents and older adults who are at an increased risk for HIV infection.” Read the AIDS.gov blog post.   April 25, 2013: Prezista (Darunavir) Labeling Changes “On April 24, 2013, FDA approved revisions to the Prezista (darunavir) tablet and oral suspens...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - May 3, 2013 Category: Infectious Diseases Source Type: news

NIH scientists create new tool for identifying powerful HIV antibodies
(NIH/National Institute of Allergy and Infectious Diseases) A team of NIH scientists has developed a new tool to identify broadly neutralizing antibodies capable of preventing infection by the majority of HIV strains found around the globe, an advance that could help speed HIV vaccine research.
Source: EurekAlert! - Infectious and Emerging Diseases - May 9, 2013 Category: Infectious Diseases Source Type: news

Recent HIV/AIDS News from NIAID and FDA
May 9, 2013: NIH Scientists Create New Tool for Identifying Powerful HIV Antibodies “A team of NIH scientists has developed a new tool to identify broadly neutralizing antibodies (bNAbs) capable of preventing infection by the majority of HIV strains found around the globe, an advance that could help speed HIV vaccine research.” Read the NIAID press release.   May 13, 2013: FDA Announces Public Meeting on HIV Patient-Focused Drug Development and HIV Cure Research “On June 14, 2013, as part of the Patient-Focused Drug Development initiative intended to enhance patient input, FDA will...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - May 17, 2013 Category: Infectious Diseases Source Type: news

Oseltamivir Pharmacology in Young Children: A Commentary.
Abstract Oseltamivir is listed by the World Health Organization as an essential drug for the treatment and prophylaxis of both seasonal and pandemic influenza. Since influenza mortality is highest in neonates and infants, optimal dosing of oseltamivir in this high risk population is of utmost public health concern. To date, only two major clinical trials have been conducted investigating oselatmivir exposure and exposure/response in neonates and infants. The first study was a prospective, open label pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir in a total of 87 young children less than 2 yea...
Source: Infectious Disorders Drug Targets - May 8, 2013 Category: Infectious Diseases Authors: Kamal MA Tags: Infect Disord Drug Targets Source Type: research

New insights into atopic dermatitis: role of skin barrier and immune dysregulation.
Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disease that is often associated with the development of food allergy and asthma. New insights into AD reveals an important role for structural abnormalities in the epidermis resulting in a leaky epithelial barrier as well as chronic immune activation that contribute to the pathophysiology of this common skin disease. Patients with AD have a predisposition to colonization or infection by microbial organisms, most notably Staphylococcus aureus and herpes simplex virus (HSV). Measures directed at healing and protecting the skin barrier and controlling th...
Source: Herpes - May 30, 2013 Category: Infectious Diseases Authors: Leung DY Tags: Allergol Int Source Type: research

Double dose of antiviral drug offers no added benefit in severe influenza
(Wellcome Trust) Giving double doses of the antiviral drug oseltamivir, or Tamiflu, offers no clinical or virological advantages over a standard dose for patients admitted to hospital with severe influenza infection, according to a randomized trial published today and funded by the Wellcome Trust, US National Institute of Allergy and Infectious Diseases and the Singapore National Medical Research Council.
Source: EurekAlert! - Infectious and Emerging Diseases - May 30, 2013 Category: Infectious Diseases Source Type: news

Updated AIDSinfo Drug Database Offers Health Professionals and Patients the Latest HIV-Related Drug Information
The latest additions to the AIDSinfo drug database provide health care providers and patients with even more information on HIV/AIDS-related drugs.   Recent improvements to the database include: Investigational HIV drug summaries for health professionals that include the most recent information on pharmacology, dosing, adverse events, and drug interactions. The drug summaries also feature drug compound details from ChemIDplus Advanced (United States National Library of Medicine) and the HIV Drugs in Development Database from the National Institute of Allergy and Infectious Diseases (NIAID). Updated HIV investigat...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - May 31, 2013 Category: Infectious Diseases Source Type: news

Establishment and application of real-time quantitative PCR for diagnosing invasive Aspergillosis via the blood in hematological patients: targeting a specific sequence of Aspergillus 28S-ITS2
Conclusions: The use of qPCR with whole blood to detect and verify the 28S-ITS2 sequence is a specific and useful way to diagnose IA.
Source: BMC Infectious Diseases - June 1, 2013 Category: Infectious Diseases Authors: Yan LiLi GaoYi DingYuanyuan XuMinhang ZhouWenrong HuangYu JingHonghua LiLili WangLi Yu Source Type: research

Recent HIV/AIDS News from CDC, FDA, and NIAID
June 12, 2013: Study Finds First Evidence That PrEP Can Reduce HIV Risk Among People Who Inject Drugs “A daily dose of a medication used to treat HIV infection reduced the risk of HIV acquisition among people who inject drugs by 49 percent. Those who took the medication most consistently had even higher levels of protection, according to a new study announced today by the Centers for Disease Control and Prevention – in collaboration with the Bangkok Metropolitan Administration (BMA) and the Thailand Ministry of Public Health (MOPH). "This is the first evidence that pre-exposure prophylaxis (PrEP)...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - June 14, 2013 Category: Infectious Diseases Source Type: news

CDC advisory committee recommends an influenza vaccine option for persons with egg allergy
Source: CDC Flu updates - June 21, 2013 Category: Infectious Diseases Source Type: news

Nigeria: Nigerian Medical Experts Applaud Investigational Malaria Vaccine
[Vanguard]NIGERIAN medical professionals have applauded the early-stage clinical evaluation of an investigational malaria vaccine known as the PfSPZ Vaccine, conducted by researchers at the National Institute of Allergy and Infectious Diseases, NIAID, part of the National Institutes of Health.
Source: AllAfrica News: Malaria - August 13, 2013 Category: Infectious Diseases Source Type: news

Investigational oral regimen for hepatitis C shows promise in NIH trial
(NIH/National Institute of Allergy and Infectious Diseases) In a study of an all-oral drug regimen, a majority of volunteers with liver damage due to hepatitis C virus infection were cured following a six-month course of therapy that combined an experimental drug, sofosbuvir, with the licensed antiviral drug ribavirin. The results showed that the regimen was highly effective in clearing the virus and well tolerated in a group of patients who historically have had unfavorable prognoses.
Source: EurekAlert! - Infectious and Emerging Diseases - August 27, 2013 Category: Infectious Diseases Source Type: news

Duke Medicine selected as new site for competitive vaccine and treatment research program
(Duke University Medical Center) Duke Medicine has been named a Vaccine and Treatment Evaluation Unit by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to evaluate vaccines, treatments and diagnostics to protect people from infectious diseases, including emerging public health needs.
Source: EurekAlert! - Infectious and Emerging Diseases - September 26, 2013 Category: Infectious Diseases Source Type: news

NIH scientists develop candidate vaccine against respiratory syncytial virus
(NIH/National Institute of Allergy and Infectious Diseases) An experimental vaccine to protect against respiratory syncytial virus (RSV), a leading cause of illness and hospitalization among very young children, elicited high levels of RSV-specific antibodies when tested in animals, according to a report in the journal Science.
Source: EurekAlert! - Infectious and Emerging Diseases - October 31, 2013 Category: Infectious Diseases Source Type: news

Recent HIV/AIDS News from NIAID, NIH, and FDA
December 18, 2013: Animal Vaccine Study Yields Insights That May Advance HIV Vaccine Research “A vaccine study in monkeys designed to identify measurable signs that the animals were protected from infection by SIV, the monkey version of HIV, as well as the mechanism of such protection has yielded numerous insights that may advance HIV vaccine research.” Read the NIAID press release.   December 17, 2013: NIH Names Leadership, Research Units for Restructured HIV/AIDS Clinical Trials Networks “Principal investigators and clinical trials units (CTUs) have been chosen to lead and conduc...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - December 20, 2013 Category: Infectious Diseases Source Type: news